

Stability Indicating Method for HIV Injection Treatment


Application #AN4170

Conditions



Column: ACE Excel 2 C18
Dimensions: 50 x 3.0 mm
Part Number: EXL-101-0503U
Mobile Phase: A: 0.1% TFA in H₂O
B: 0.1% TFA in MeCN

Time (mins)	%B
0.0	10
3.0	90
6.0	90
6.1	10
8.0	10



Flow Rate: 0.4 mL/min
Injection: 20 µL
Temperature: 30 °C
Detection: UV, 240 nm




1. Emtricitabine
(LLOQ 0.10 µg/mL)



2. Tenofovir disoproxil
(LLOQ 0.10 µg/mL)



3. Cobicistat
(LLOQ 0.20 µg/mL)



4. Elvitegravir
(LLOQ 0.02 µg/mL)

Revath Naga Lakshmi P., Prahlad P., Mastananna SK., Ravindra N., Venkata Basaveswara Rao M, UPLC Separation Analysis of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir from their Degradation products, Int. J. Pharm & Pharm Sci, 8(4), 362- 369 (2016)

© 2015 ACT Ltd. All rights reserved. All products are available worldwide.